迈威生物股价九连阴 2022上市募34.77亿海通证券保荐

Core Viewpoint - Maiwei Biotech's stock has been declining for nine consecutive trading days, currently trading at 18.38 yuan, which is below its initial offering price of 34.80 yuan [1][2]. Group 1: Company Financials - Maiwei Biotech was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on January 18, 2022, with a total issuance of 99.90 million shares [1]. - The total amount raised from the initial public offering (IPO) was 3.477 billion yuan, with a net amount of 3.303 billion yuan after deducting issuance costs [1]. - The final net fundraising amount exceeded the original plan by 323 million yuan [1]. - The company planned to raise 2.980 billion yuan for projects including the construction of a 1000 kg antibody production facility, antibody drug research and development, and to supplement working capital [1]. Group 2: Underwriting and Strategic Placement - Haitong Securities arranged for its subsidiary, Haitong Innovation Securities Investment Co., Ltd., to participate in the strategic placement of the IPO, acquiring 2.88% of the total issuance, amounting to approximately 9.999 million yuan [2]. - The lock-up period for the shares acquired by Haitong Innovation Securities is set for 24 months from the date of listing [2].